Abstract 9P
Background
Breast cancer is identified as a leading cancer in Kyrgyz females. Poor diagnostic approaches lead to high rate of advanced breast cancer cases and consequently to a high mortality rate. Genetic testing is a promising method of prevention and early diagnosis of breast cancer.
Methods
This was a case-control study of 201 women of the Kyrgyz ethnic group with a morphologically verified breast cancer (N=99) and 102 controls age-matched with BC cases. The mean age of the patients was 48 years (minimum 24, maximum 74, STD=9.83). The extraction of DNA was carried out from venous blood. The genotyping was performed by using restriction fragment length polymorphism assay.
Results
Genotype CT of the polymorphic variant V353A HMMR gene has been defined as protective factor and decreases the risk of developing of breast cancer in the Kyrgyz population (OR=0,481, 95%CI 0,272 – 0,850, р=0,011). As well as combinations of the allele 194Trp (XRCC1 Arg194Trp) and genotype СТ (HMMR V353A) (OR=0,302, [95% CI 0,128-0,713], р=0,005), CT/TT (OR=0,459, 95% CI [0,259-0,814], р=0,007) of HMMR V353A and Palb2 T1100T (3300T>G)polymorphisms, CT/GG (OR=0,546, 95% CI [0,298-0,999], р=0,048) of HMMR V353A and TNF aG3080A polymorphisms are associated with decreased risk of developing of breast cancer in the Kyrgyz ethnic group. Furthermore, the allele 194Trp is associated with late age of diagnosis of breast cancer when comparing to 194Arg allele of XRCC1 gene (p=0,017), more often occurs in postmenopausal women (p=0,005) and in women with high BMI (>25) (p=0,003).
Conclusions
The above genotypes may be used as markers for evaluation of the risk of breast cancer in the Kyrgyz ethnic group.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
274P - Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene
Presenter: Raimkul Karakulov
Session: Poster display session
Resources:
Abstract
275P - Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam
Presenter: Gia Nguyen Hoang
Session: Poster display session
Resources:
Abstract
276P - Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis
Presenter: GEDALA Veni Prasanna
Session: Poster display session
Resources:
Abstract
277P - Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia
Presenter: Zeeshan Ahmed
Session: Poster display session
Resources:
Abstract
278P - A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma
Presenter: Gautamjeet Mangat
Session: Poster display session
Resources:
Abstract
280P - Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL
Presenter: Kundan Mishra
Session: Poster display session
Resources:
Abstract
281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
Presenter: Jing Sun
Session: Poster display session
Resources:
Abstract
282P - Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling
Presenter: Nidh Gupta
Session: Poster display session
Resources:
Abstract
283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis
Presenter: Jinhyun Cho
Session: Poster display session
Resources:
Abstract